Fig. 1.

Change in mTSS from baseline to week 24 in subjects grouped by disease activity and treatment

(A) TA-DAS28(CRP); (B) TA-DAPSA; (C) TA-PASDAS; (D) MDA status at week 24. *P < 0.05, **P < 0.01, ***P < 0.001 for ADA vs PBO. Error bars indicate s.d. ADA: adalimumab; DAS28: Disease Activity Score of 28 joints; MDA: minimal disease activity; mTSS: modified total Sharp score; DAPSA, Disease Activity Index for Psoriatic Arthritis; PASDAS: Psoriatic Arthritis Disease Activity Score; PBO: placebo; TA: time averaged.